

PRAXIS PRECISION MEDICINES, INC.

Reported by
MASTROCOLA LAUREN

FORM 4 (Statement of Changes in Beneficial Ownership)

Filed 11/21/25 for the Period Ending 11/20/25

Address 99 HIGH STREET, 30TH FLOOR
 BOSTON, MA, 02110

Telephone 617-300-8460

 CIK 0001689548

Symbol PRAX

SIC Code 2834 - Pharmaceutical Preparations

Industry Biotechnology & Medical Research

Sector Healthcare

Fiscal Year 12/31

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Mastrocola Lauren (Last) (First) (Middle)			2. Issuer Name and Ticker or Trading Symbol Praxis Precision Medicines, Inc. [PRAX]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> X Officer (give title below) <input type="checkbox"/> Other (specify below) Principal Accounting Officer		
C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR (Street)			3. Date of Earliest Transaction (MM/DD/YYYY) 11/20/2025							
BOSTON, MA 02110 (City) (State) (Zip)			4. If Amendment, Date Original Filed (MM/DD/YYYY)					6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	3A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/20/2025		M		1,047	A	\$49.5		11,488.656	D
Common Stock	11/20/2025		M		508	A	\$83.85		11,996.656	D
Common Stock	11/20/2025		M		1,557	A	\$133.65		13,553.656	D
Common Stock	11/20/2025		M		2,680	A	\$43.37		16,233.656	D
Common Stock	11/20/2025		M		207	A	\$44.4		16,440.656	D
Common Stock	11/20/2025		M		2,351	A	\$44.4		18,791.656	D
Common Stock	11/20/2025		M		5,250	A	\$56.94		24,041.656	D
Common Stock	11/20/2025		S		11,455	D	\$191,958 ⁽¹⁾		12,586.656	D
Common Stock	11/20/2025		S		2,145	D	\$192,711 ⁽²⁾		10,441.656	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					
Stock Option (Right to Buy)	\$49.5	11/20/2025		M		1,047	(3)	9/23/2029	Common Stock	1,047	\$0	0	D
Stock Option (Right to Buy)	\$83.85	11/20/2025		M		508	(4)	6/4/2030	Common Stock	508	\$0	0	D
Stock Option (Right to Buy)	\$133.65	11/20/2025		M		1,557	(5)	9/13/2030	Common Stock	1,557	\$0	0	D
Stock Option (Right to Buy)	\$43.37	11/20/2025		M		2,680	(6)	1/12/2034	Common Stock	2,680	\$0	9,320	D
Stock Option (Right to Buy)	\$44.4	11/20/2025		M		207	1/12/2023	1/12/2033	Common Stock	207	\$0	0	D
Stock Option (Right to Buy)	\$44.4	11/20/2025		M		2,351	(7)	1/12/2033	Common Stock	2,351	\$0	981	D
Stock Option (Right to Buy)	\$56.94	11/20/2025		M		5,250	(8)	7/29/2034	Common Stock	5,250	\$0	11,376	D

Explanation of Responses:

(1) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from \$191.500 to \$192.432. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

(2) The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from \$192.552 to \$193.109. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

(3) This option was fully vested as of January 1, 2023.

(4) This option was fully vested as of May 28, 2024.

(5) This option was fully vested as of September 8, 2024.

(6) The shares underlying this stock option vested as to 50% on January 12, 2024 and the remaining 50% vesting over a four-year period, with 25% of such shares vesting on January 12, 2025 and the remaining vesting in substantially equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each vesting date.

(7) The shares underlying this stock option vested as to 25% on January 12, 2024 and the remaining shares vest in substantially equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each vesting date.

(8) The shares underlying this stock option vested as to 7/48ths on July 29, 2024 and the remaining shares vest in substantially equal monthly installments over the following 41 months, subject to the Reporting Person's continued service through each vesting date.

Remarks:

The transactions reported in this Form 4 were effected for estate planning purposes.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Mastrocola Lauren C/O PRAXIS PRECISION MEDICINES, INC. 99 HIGH STREET, 30TH FLOOR BOSTON, MA 02110			Principal Accounting Officer	

Signatures

/s/ Alex Nemiroff, as Attorney-in-Fact

11/21/2025

**Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.